The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.
What Is The Estimated Growth In Market Size Of The Liver Cancer Diagnostics Market During 2026–2030?
The liver cancer diagnostics market size has witnessed significant expansion in recent years. It is anticipated to expand from $10.32 billion in 2025 to $11.07 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 7.3%. The drivers for this growth over the historic period include the increasing prevalence of chronic liver diseases, a rising incidence of hepatocellular carcinoma, the expansion of hospital diagnostic infrastructure, growing awareness of early cancer screening, and advancements in imaging and pathology techniques.
The liver cancer diagnostics market is anticipated to experience substantial expansion in the coming years, with its size projected to reach $14.75 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 7.4%. This growth during the forecast period is attributed to several factors, including the increasing adoption of precision oncology diagnostics, a rising demand for non-invasive diagnostic methods, the broadening of molecular testing capabilities, growing investments in oncology research, and the expanding use of AI-assisted diagnostic platforms. Major trends expected in the forecast period encompass a wider adoption of advanced molecular diagnostic tests, increased reliance on imaging-based tools for early detection, the growing integration of biomarker-based screening methods, an expansion of personalized oncology diagnostics, and an enhanced focus on identifying cancer at its early stages.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=10481&type=smp
What Market Drivers Are Helping Shape The Liver Cancer Diagnostics Market Expansion?
The expanding occurrence of liver cancer is anticipated to propel the advancement of the liver cancer diagnostics market in the coming years. Liver cancer describes a serious illness where liver cells multiply and grow beyond control. Liver cancer diagnostic tests are conducted to determine if cancer cells are spreading within or around the liver after an initial diagnosis of primary liver carcinoma, hence the increasing prevalence of liver cancer boosts the liver cancer diagnostics market. For instance, in January 2023, the Cancer Facts & Figures 2023 report, issued by the American Cancer Society, a US-based voluntary health organization, stated that the number of new cases of liver and intrahepatic bile duct cancer in US females reached 13,230 in 2023. Furthermore, in 2023, approximately 41,210 new cases of liver cancer were identified in the US, with 29,380 people projected to die. Therefore, the growing prevalence of liver cancer is a key driver for the growth of the liver cancer diagnostic market.
How Is The Liver Cancer Diagnostics Market Distributed Across Key Segments?
The liver cancer diagnostics market covered in this report is segmented –
1) By Type: Hepatocellular Carcinoma, Cholangiocarcinoma, Hepatoblastoma
2) By Screening: Laboratory Testing, Imaging, Biopsy, Other Screenings
3) By Technology: Fluorescent In Situ Hybridization (FISH), Immunohistochemical (IHC), Other Technologies
4) By End Use: Hospitals And Diagnostic Laboratories, Academic And Research Institutes
Subsegments:
1) By Hepatocellular Carcinoma: Early-Stage Hepatocellular Carcinoma, Advanced-Stage Hepatocellular Carcinoma
2) By Cholangiocarcinoma: Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma
3) By Hepatoblastoma: Pure Hepatoblastoma, Mixed Hepatoblastoma
Which Trends Are Guiding The Development Of The Liver Cancer Diagnostics Market?
Prominent companies operating in the liver cancer diagnostics market are developing advanced biomarker-based assays and algorithms to improve diagnostic accuracy and support early detection. These biomarker-based assays and algorithms refer to diagnostic tools that utilize specific biological markers to identify diseases, providing more precise and efficient diagnostic capabilities. For instance, in November 2023, Roche Diagnostics, a US-based biotech corporation, launched the Elecsys PIVKA-II assay and Elecsys GAAD algorithm. The Elecsys PIVKA-II assay detects elevated levels of the PIVKA-II biomarker, which is associated with hepatocellular carcinoma (HCC), improving early detection of liver cancer in high-risk patients. The Elecsys GAAD algorithm integrates multiple diagnostic markers, such as PIVKA-II and AFP, to enhance diagnostic precision and streamline decision-making in liver cancer detection.
Which Companies Form The Competitive Landscape Of The Liver Cancer Diagnostics Market?
Major companies operating in the liver cancer diagnostics market are Abbott Laboratories, F Hoffmann La Roche Ltd, Qiagen NV, Thermo Fisher Scientific Inc, Siemens Healthineers, Illumina Inc, Koninklijke Philips NV, Epigenomics AG, Digna Biotech SL, Biocept Inc, Danaher Corporation, Foundation Medicine Inc, Agilent Technologies Inc, Genemed Biotechnologies Inc, Merck KGaA, Fujifilm Medical Systems USA Inc, GE Healthcare, Advanced Cell Diagnostics Inc, Oxford Gene Technology, Leica Biosystems Nussloch GmbH, Exiqon AS, BioGenex Laboratories Inc, OncoCyte Corporation, Guardant Health Inc, Exact Sciences Corporation, Grail Inc, Freenome Holdings Inc, Natera Inc, Personal Genome Diagnostics Inc, Thrive Earlier Detection Corp
Access The Complete Liver Cancer Diagnostics Market Report:
https://www.thebusinessresearchcompany.com/report/liver-cancer-diagnostics-global-market-report
Which Region Is The Primary Market For The Liver Cancer Diagnostics Market?
North America was the largest region in the liver cancer diagnostics market in 2025. The regions covered in the liver cancer diagnostics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Access a Liver Cancer Diagnostics Market Report for Deeper Competitive Insights
https://www.thebusinessresearchcompany.com/report/liver-cancer-diagnostics-global-market-report
Browse Through More Reports Similar to the Global Liver Cancer Diagnostics Market 2026, By The Business Research Company
Liver Health Supplements Market Report 2026
https://www.thebusinessresearchcompany.com/report/liver-health-supplements-global-market-report
Cancer Diagnostics Market Report 2026
https://www.thebusinessresearchcompany.com/report/cancer-diagnostics-global-market-report
Unresectable Hepatocellular Carcinoma Market Report 2026
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model